Therapy for β-globinopathies: A brief review and determinants for successful and safe correction

Annals of the New York Academy of Sciences

Volumn 1202, Issue , 2010, Pages 36-44

  Perumbeti, Ajay ^a   Malik, Punam ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

gene therapy; insulators; lentivirus vectors; sickle cell disease; thalassemia

Indexed keywords

BETA GLOBIN; CD34 ANTIGEN; GAMMA GLOBIN; GLYCOPHORIN A; HEMOGLOBIN F; HOX PROTEIN; LENTIVIRUS VECTOR;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; GENE THERAPY; GENE TRANSFER; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; PLURIPOTENT STEM CELL; SICKLE CELL ANEMIA; THALASSEMIA; XENOGRAFT;

EID: 77955905020     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05584.x     Document Type: Conference Paper

References (39)

1. Kauf, T.L., T.D. Coates, L. Huazhi, et al. 2009. The cost of health care for children and adults with sickle cell disease. Am. J. Hematol. 84: 323-327.
2. Aiuti, A. et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.N. Engl. J. Med. 360: 447-458.
3. Hacein-Bey-Abina, S. et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, N.Y.) 302: 415-419.
4. Hacein-Bey-Abina, S. et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCIDX1. J. Clin. Invest. 118: 3132-3142.
5. Gaspar, H.B. et al. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
6. Ott, M.G. et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12: 401-409.
7. Mohamedali, A. et al. 2004. Self-inactivating lentiviral vectors resist proviral methylation but do not confer positionindependent expression in hematopoietic stem cells. Mol. Ther. 10: 249-259.
8. Arumugam, P.I. et al. 2007. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element. Mol. Ther. 15: 1863-1871.
9. Perumbeti, A. et al. 2009. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 114: 1174-1185.
10. Challita, P.M. & D.B. Kohn. 1994. Lack of expression from a retroviral vector after transduction ofmurine hematopoietic stem cells is associated with methylation in vivo. Proc. Natl. Acad. Sci. USA 91: 2567-2571.
11. Stein, S. et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med. 16: 198-204.
12. Ciavatta, D.J., T.M. Ryan, S.C. Farmer & T.M. Townes. 1995. Mousemodel of human beta zero thalassemia: targeted deletion of the mouse beta maj- and beta min-globin genes in embryonic stem cells. Proc. Natl. Acad. Sci. USA 92: 9259-9263.
13. Rivella, S., C. May, A. Chadburn, et al. 2003. A novel murine model of Cooley anemia and its rescue by lentiviralmediatedhumanbeta- globin gene transfer. Blood 101: 2932-2939.
14. Imren, S. et al. 2002.Permanent and panerythroid correction ofmurine beta thalassemia bymultiple lentiviral integration in hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 99: 14380-14385.
15. Emery, D.W. et al. 2002. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100: 2012-2019.
16. Persons, D.A., P.W. Hargrove, Allay, E.R., et al. 2003. The degree of phenotypic correction of murine beta-thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal positioneffects and vector copynumber. Blood 101: 2175-2183.
17. Puthenveetil, G. et al. 2004. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 104: 3445-3453.
18. Miccio, A. et al. 2008. In vivo selection of genetically modified erythroblastic progenitors leads to long-termcorrection of beta-thalassemia. Proc. Natl. Acad. Sci. USA 105: 10547-10552.
19. Lisowski, L. & M. Sadelain. 2007. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. Blood 110: 4175-4178.
20. Hanawa, H. et al. 2004. Extended beta-globin locus control region elements promote consistent therapeutic expression of a gamma-globin lentiviral vector in murine betathalassemia. Blood 104: 2281-2290.
21. Kaiser, J. 2009. Gene therapy. Beta-thalassemia treatment succeeds, with a caveat. Science (New York, N.Y.) 326: 1468-1469.
22. Paszty, C. et al. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (New York, N.Y.) 278: 876-878.
23. Levasseur, D.N., T.M. Ryan, K.M. Pawlik & T.M. Townes. 2003. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102: 4312-4319.
24. Wu, L.C. et al. 2006. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108: 1183-1188.
25. McCune, S.L., M.P. Reilly, M.J. Chomo, et al. 1994. Recombinant human hemoglobins designed for gene therapy of sickle cell disease. Proc. Natl. Acad. Sci. USA 91: 9852-9856.
26. Levasseur, D.N. et al. 2004. A recombinant human hemoglobin with anti-sickling properties greater than fetal hemoglobin. J. Biol. Chem. 279: 27518-27524.
27. Oh, I.H., A. Lau & C.J. Eaves. 2000. During ontogeny primitive (CD34(+)CD38(?)) hematopoietic cells show altered expression of a subset of genes associated with early cytokine and differentiation responses of their adult counterparts. Blood 96: 4160-4168.
28. Pawliuk, R. et al. 2001. Correction of sickle cell disease in transgenicmousemodelsbygene therapy. Science (NewYork, N.Y.) 294: 2368-2371.
29. Samakoglu, S. et al. 2006. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat. Biotechnol. 24: 89-94.
30. Pestina, T.I. et al. 2009. Correction of murine sickle cell disease using gamma-globin lentiviral vectors to mediate high-level expression of fetal hemoglobin. Mol. Ther. 17: 245-252.
31. Hanna, J. et al. 2007. Treatment of sickle cell anemia mouse modelwith iPS cells generated from autologous skin. Science (New York, N.Y.) 318: 1920-1923.
32. Qiu, C., E.N. Olivier, M. Velho & E.E. Bouhassira. 2008. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood 111: 2400-2408.
33. Lengerke, C. et al. 2009. Hematopoietic development from human induced pluripotent stem cells. Ann. N.Y. Acad. Sci. 1176: 219-227.
34. Maruggi, G. et al. 2009. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 17: 851-856.
35. Imren, S. et al. 2004. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J. Clin. Invest. 114: 953-962.
36. Hargrove, P.W. et al. 2008. Globin lentiviral vector insertions can perturb the expression of endogenous genes in betathalassemic hematopoietic cells. Mol. Ther. 16: 525-533.
37. Li, C.L., D. Xiong, G. Stamatoyannopoulos & D.W. Emery. 2009. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol. Ther. 17: 716-724.
38. Jimenez, G., S.D. Griffiths, A.M. Ford, et al. 1992. Activation of the beta-globin locus control region precedes commitment to the erythroid lineage. Proc. Natl. Acad. Sci. USA 89: 10618-10622.
39. Arumugam, P.I. et al. 2009. Genotoxic potential of lineagespecific lentivirus vectors carrying the beta-Globin locus control region. Mol. Ther. 17: 1929-1937.